Search

Your search keyword '"Holmberg, Leona A."' showing total 566 results
Start Over Author "Holmberg, Leona A."
566 results on '"Holmberg, Leona A."'

101. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation

Author

Brunstein, Claudio G., primary, Pasquini, Marcelo C., additional, Kim, Soyoung, additional, Fei, Mingwei, additional, Adekola, Kehinde, additional, Ahmed, Ibrahim, additional, Aljurf, Mahmoud, additional, Agrawal, Vaibhav, additional, Auletta, Jeffrey J., additional, Battiwalla, Minoo, additional, Bejanyan, Nelli, additional, Bubalo, Joseph, additional, Cerny, Jan, additional, Chee, Lynette, additional, Ciurea, Stefan O., additional, Freytes, Cesar, additional, Gadalla, Shahinaz M., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hildebrandt, Gerhard, additional, Holmberg, Leona A., additional, Lahoud, Oscar B., additional, Landau, Heather, additional, Lazarus, Hillard M., additional, de Lima, Marcos, additional, Mathews, Vikram, additional, Maziarz, Richard, additional, Nishihori, Taiga, additional, Norkin, Maxim, additional, Olsson, Richard, additional, Reshef, Ran, additional, Rotz, Seth, additional, Savani, Bipin, additional, Schouten, Harry C., additional, Seo, Sachiko, additional, Wirk, Baldeep M., additional, Yared, Jean, additional, Mineishi, Shin, additional, Rogosheske, John, additional, and Perales, Miguel-Angel, additional

Published
2019
Full Text
View/download PDF

102. Safety and Toxicities of Radiotherapy As Consolidation or Cytoreduction Around the Time of Autologous Stem Cell Transplantation for Multiple Myeloma Patients: A Single Center Retrospective Report

Author

Kopmar, Noam E., primary, Tseng, Yolanda D., additional, Holmberg, Leona A., additional, Becker, Pamela S., additional, Green, Damian J., additional, Tuazon, Sherilyn, additional, Libby, Edward N., additional, Coffey, David G., additional, Gopal, Ajay K., additional, and Cowan, Andrew J., additional

Published
2019
Full Text
View/download PDF

103. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups

Author

Scott, Emma C., primary, Hari, Parameswaran, additional, Kumar, Sathish, additional, Fraser, Raphael, additional, Davila, Omar, additional, Shah, Nina, additional, Gale, Robert Peter, additional, Diaz, Miguel Angel, additional, Agrawal, Vaibhav, additional, Cornell, Robert F., additional, Ganguly, Siddhartha, additional, Akpek, Gorgun, additional, Freytes, Cesar, additional, Hashmi, Shahrukh, additional, Malek, Ehsan, additional, Kamble, Rammurti T., additional, Lazarus, Hillard, additional, Solh, Melhem, additional, Usmani, Saad Z., additional, Kanate, Abraham S., additional, Saad, Ayman, additional, Chhabra, Saurabh, additional, Gergis, Usama, additional, Cerny, Jan, additional, Kyle, Robert A., additional, Lee, Cindy, additional, Kindwall-Keller, Tamila, additional, Assal, Amer, additional, Hildebrandt, Gerhard C., additional, Holmberg, Leona, additional, Maziarz, Richard T., additional, Nishihori, Taiga, additional, Seo, Sachiko, additional, Kumar, Shaji, additional, Mark, Tomer, additional, and D'Souza, Anita, additional

Published
2018
Full Text
View/download PDF

104. Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

Author

Cowan, Andrew J., primary, Stevenson, Philip A., additional, Kopmar, Noam, additional, Libby, Edward N., additional, Becker, Pamela S., additional, Coffey, David G., additional, Tuazon, Sherilyn A., additional, Green, Damian J., additional, Gopal, Ajay K., additional, and Holmberg, Leona A., additional

Published
2018
Full Text
View/download PDF

108. 480 - Multifocal Not Single-Site FDG-PET Residual Disease Prior to Autologous Stem Cell Transplant for Hodgkin Lymphoma Associated with Adverse Outcome

Author

Panaite, Lorena, Behnia, Fatemeh, Stevenson, Philip A., Gooley, Ted A., Mireles, Lily, Karami, Mehdi, Tseng, Yolanda D., Chung, Karen H, Smith, Stephen D., Lynch, Ryan C., Ujjani, Chaitra S, Georges, George E., Shustov, Andrei R., Till, Brian G., Gauthier, Jordan, Chow, Victor A., Maloney, David G., Gopal, Ajay K., Holmberg, Leona A., and Shadman, Mazyar

Published
2021
Full Text
View/download PDF

109. Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

Author

Tuazon, Sherilyn A., Cassaday, Ryan D., Gooley, Theodore A., Sandmaier, Brenda M., Holmberg, Leona A., Smith, Stephen D., Maloney, David G., Till, Brian G., Martin, Daniel B., Chow, Victor A., Rajendran, Joseph G., Fisher, Darrell R., Matesan, Manuela C., Lundberg, Sally J., Green, Damian J., Pagel, John M., Press, Oliver W., and Gopal, Ajay K.

Abstract

•CD45 is ubiquitously expressed across all lymphoma subtypes.•High doses of 90Y-conjugated to anti-CD45 antibodies can be safely combined with BEAM (carmustine, etoposide, cytarabine, melphalan) for lymphoma.•Early signs of short- and long-term efficacy were observed.

Published
2024
Full Text
View/download PDF

110. New Cancers after Autotransplantations for Multiple Myeloma

Author

Mahindra, Anuj, Raval, Girindra, Mehta, Paulette, Brazauskas, Ruta, Zhang, Mei-Jie, Zhong, Xiaobo, Bird, Jennifer M., Freytes, César O., Hale, Gregory A., Herzig, Roger, Holmberg, Leona A., Kamble, Rammurti T., Kumar, Shaji, Lazarus, Hillard M., Majhail, Navneet S., Marks, David I., Moreb, Jan S., Olsson, Richard, Saber, Wael, Savani, Bipin N., Schiller, Gary J., Tay, Jason, Vogl, Dan T., Waller, Edmund K., Wiernik, Peter H., Wirk, Baldeep, Lonial, Sagar, Krishnan, Amrita Y., Dispenzieri, Angela, Brandenburg, Nancy A., Gale, Robert Peter, and Hari, Parameswaran

Abstract

We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7 years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P = .0004), and 3.58 (99% CI, 1.82 to 6.29; P< .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.

Published
2024
Full Text
View/download PDF

111. Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma.

Author

Holmberg, Leona A., Green, Damian, Libby, Edward, and Becker, P.S.

Subjects
*AUTOGRAFTS, *MULTIPLE myeloma, *BORTEZOMIB, *HEMATOPOIETIC stem cells, *STEM cell transplantation
Abstract

Background: In multiple myeloma (MM), relapse is a frequent complication after autologous hematopoietic stem cell transplant (ASCT). To reduce the risk of relapse, additional therapy has been added post-ASCT. In a nontransplant relapse setting, the combination of intravenous bortezomib and oral vorinostat (BV) was studied and showed efficacy. Therefore, it was reasonable to study this combination therapy post-ASCT. Patients and Methods: We report on BV given post-ASCT. All 30 patients underwent conditioning for ASCT with high-dose melphalan. After recovery from the acute transplant-related toxicity, BV therapy was started and given for a total of 12 (28-day) cycles. Results: The most common toxicities were hematological, gastrointestinal (diarrhea and nausea), fatigue, and peripheral neuropathy. The median follow-up for BV patients is 7.8 (range: 6.12–9.03) years. After BV therapy, 18 patients (60%) are alive, and 9 (30%) are alive without disease progression. Conclusions: BV can be given post-ASCT with an acceptable toxicity profile and produces reasonable disease-free and overall survival rates. A randomized study comparing the BV regimen to single-agent lenalidomide or bortezomib is needed. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

112. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma

Author

Maffini, Enrico, primary, Storer, Barry E., additional, Sandmaier, Brenda M., additional, Bruno, Benedetto, additional, Sahebi, Firoozeh, additional, Shizuru, Judith A., additional, Chauncey, Thomas R., additional, Hari, Parameswaran, additional, Lange, Thoralf, additional, Pulsipher, Michael A., additional, McSweeney, Peter A., additional, Holmberg, Leona, additional, Becker, Pamela S., additional, Green, Damian J., additional, Mielcarek, Marco, additional, Maloney, David G., additional, and Storb, Rainer, additional

Published
2018
Full Text
View/download PDF

113. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Author

Smith, Sonali M., primary, Godfrey, James, additional, Ahn, Kwang Woo, additional, DiGilio, Alyssa, additional, Ahmed, Sairah, additional, Agrawal, Vaibhav, additional, Bachanova, Veronika, additional, Bacher, Ulrike, additional, Bashey, Asad, additional, Bolaños‐Meade, Javier, additional, Cairo, Mitchell, additional, Chen, Andy, additional, Chhabra, Saurabh, additional, Copelan, Edward, additional, Dahi, Parastoo B., additional, Aljurf, Mahmoud, additional, Farooq, Umar, additional, Ganguly, Siddhartha, additional, Hertzberg, Mark, additional, Holmberg, Leona, additional, Inwards, David, additional, Kanate, Abraham S., additional, Karmali, Reem, additional, Kenkre, Vaishalee P., additional, Kharfan‐Dabaja, Mohamed A., additional, Klein, Andreas, additional, Lazarus, Hillard M., additional, Mei, Matthew, additional, Mussetti, Alberto, additional, Nishihori, Taiga, additional, Ramakrishnan Geethakumari, Praveen, additional, Saad, Ayman, additional, Savani, Bipin N., additional, Schouten, Harry C., additional, Shah, Nirav, additional, Urbano‐Ispizua, Alvaro, additional, Vij, Ravi, additional, Vose, Julie, additional, Sureda, Anna, additional, and Hamadani, Mehdi, additional

Published
2018
Full Text
View/download PDF

114. Long Term Follow Up (LTFU) after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma and Multiple Myeloma: An Analysis of Patient Self-Reported Outcomes of Medical Conditions and Quality of Life (QOL)

Author

Georges, George E., primary, Onstad, Lynn, additional, Flowers, Mary E., additional, Carpenter, Paul A., additional, Yi, Jean C., additional, Bar, Merav, additional, Shadman, Mazyar, additional, Stewart, Susan, additional, Lee, Stephanie J., additional, and Holmberg, Leona A., additional

Published
2018
Full Text
View/download PDF

116. Safety and Efficacy of Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

Author

Cassaday, Ryan D., primary, Press, Oliver W., additional, Pagel, John M., additional, Rajendran, Joseph G., additional, Gooley, Ted Alan, additional, Fisher, Darrell R., additional, Miyaoka, Robert S., additional, Maloney, David G., additional, Smith, Stephen D., additional, Till, Brian G., additional, Martin, Daniel B., additional, Holmberg, Leona A., additional, Green, Damian J., additional, and Gopal, Ajay K., additional

Published
2018
Full Text
View/download PDF

117. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Alsina, Melissa, additional, Atanackovic, Djordje, additional, Biermann, J. Sybil, additional, Castillo, Jorge, additional, Chandler, Jason C., additional, Costello, Caitlin, additional, Faiman, Matthew, additional, Fung, Henry C., additional, Godby, Kelly, additional, Hofmeister, Craig, additional, Holmberg, Leona, additional, Holstein, Sarah, additional, Huff, Carol Ann, additional, Kang, Yubin, additional, Kassim, Adetola, additional, Liedtke, Michaela, additional, Malek, Ehsan, additional, Martin, Thomas, additional, Neppalli, Vishala T., additional, Omel, James, additional, Raje, Noopur, additional, Singhal, Seema, additional, Somlo, George, additional, Stockerl-Goldstein, Keith, additional, Weber, Donna, additional, Yahalom, Joachim, additional, Kumar, Rashmi, additional, and Shead, Dorothy A., additional

Published
2018
Full Text
View/download PDF

119. A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Author

Tuazon, Sherilyn A, primary, Sandmaier, Brenda M., additional, Orozco, Johnnie J., additional, Gopal, Ajay K., additional, Holmberg, Leona A., additional, Becker, Pamela S., additional, Lundberg, Sally J., additional, Till, Brian G., additional, Nartea, Margaret E., additional, Gooley, Ted, additional, Fisher, Darrell R., additional, Rajendran, Joseph G., additional, Press, Oliver W., additional, Bensinger, William I., additional, and Green, Damian J., additional

Published
2017
Full Text
View/download PDF

120. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma

Author

Green, Damian J., primary, Maloney, David G., additional, Storer, Barry E., additional, Sandmaier, Brenda M., additional, Holmberg, Leona A., additional, Becker, Pamela S., additional, Fang, Min, additional, Martin, Paul J., additional, Georges, George E., additional, Bouvier, Michelle E., additional, Storb, Rainer, additional, and Mielcarek, Marco, additional

Published
2017
Full Text
View/download PDF

122. NCCN Guidelines® Insights Multiple Myeloma, Version 3.2016: Featured Updates to the NCCN Guidelines

Author

Anderson, Kenneth C., Alsina, Melissa, Atanackovic, Djordje, Biermann, J. Sybil, Chandler, Jason C., Costello, Caitlin, Djulbegovic, Benjamin, Fung, Henry C., Gasparetto, Cristina, Godby, Kelly, Hofmeister, Craig, Holmberg, Leona, Holstein, Sarah, Huff, Carol Ann, Kassim, Adetola, Krishnan, Amrita Y., Kumar, Shaji K., Liedtke, Michaela, Lunning, Matthew, Raje, Noopur, Reu, Frederic J., Singhal, Seema, Somlo, George, Stockerl-Goldstein, Keith, Treon, Steven P., Weber, Donna, Yahalom, Joachim, Shead, Dorothy A., and Kumar, Rashmi

Subjects
hemic and lymphatic diseases, Humans, sense organs, skin and connective tissue diseases, Multiple Myeloma, Article
Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.

Published
2016

123. Effect of acute and chronic graft-versus-host disease on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma

Author

Ringdén, Olle, Shrestha, Smriti, da Silva, Gisela Tunes, Zhang, Mei-Jie, Dispenzieri, Angela, Remberger, Mats, Kamble, Rammurti, Freytes, Cesar O., Gale, Robert Peter, Gibson, John, Gupta, Vikas, Holmberg, Leona, Lazarus, Hillard, McCarthy, Philip, Meehan, Kenneth, Schouten, Harry, Milone, Gustavo A., Lonial, Sagar, and Hari, Parameswaran N

Subjects
Adult, Male, Transplantation Conditioning, Graft vs Host Disease, chemical and pharmacologic phenomena, Graft-versus-host disease, Article, Disease-Free Survival, immune system diseases, reduced intensity, Risk Factors, hemic and lymphatic diseases, Humans, Transplantation, Homologous, Aged, Retrospective Studies, allogeneic, Graft vs Tumor Effect, Hematopoietic Stem Cell Transplantation, Middle Aged, Survival Rate, surgical procedures, operative, myeloma, Acute Disease, Chronic Disease, Female, Multiple Myeloma
Abstract

We evaluated the effect of acute and chronic graft-versus-host disease (GVHD) on relapse and survival after allogeneic haematopoietic stem cell transplantation (HSCT) for multiple myeloma (MM) using non-myeloablative conditioning (NMA) and reduced-intensity conditioning (RIC). The outcomes of 177 HLA-identical sibling HSCT recipients between 1997 and 2005 following NMA (n=98) or RIC (n=79) were analyzed. In 105 patients, autografting was followed by planned NMA/RIC allogeneic transplantation. The impact of GVHD was assessed as a time-dependent covariate using Cox models. The incidence of acute GVHD (grades I–IV) was 42% (95% confidence interval (CI) 35 – 49%) and of chronic GVHD at five years was 59% (95% CI 49 – 69%), with 70% developing extensive chronic GVHD. In multivariate analysis, acute GVHD (≥ grade I) was associated with an increased risk of TRM (relative risk (RR)=2.42; p=0.016), whereas limited chronic GVHD significantly decreased the risk of myeloma relapse (RR=0.35, p=0.035) and was associated with superior event-free survival (RR=0.40, p=0.027). Acute GVHD had a detrimental effect on survival, especially in those receiving autologous followed by allogeneic HSCT (RR=3.52; p=0.001). The reduction in relapse risk associated with chronic GVHD is consistent with a beneficial graft-versus-myeloma effect, but this did not translate into a survival advantage.

Published
2011

125. Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era

Author

Sabloff, Mitchell, primary, Wang, Tao, additional, Zhu, Xiaochun, additional, Artz, Andrew S., additional, Adekola, Kehinde, additional, Abraham, Allistair, additional, Auletta, Jeffery J., additional, Battiwalla, Minoo, additional, Beitinjaneh, Amer, additional, Bredeson, Christopher N., additional, Bufarull, Rodrigo Martino, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Chhabra, Saurabh, additional, Copelan, Edward A., additional, Daly, Andrew, additional, Dias, Ajoy, additional, Diaz, Miguel Angel, additional, Freytes, Cesar O., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hale, Gregory A., additional, Hamilton, Betty Ky, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hildebrandt, Gerhard C., additional, Holmberg, Leona A., additional, Hong, Sanghee, additional, Kekre, Natasha, additional, Lazarus, Hillard M., additional, Lazaryan, Aleksandr, additional, Luger, Selina M., additional, Muffly, Lori, additional, Nagler, Arnon, additional, Nishihori, Taiga, additional, Norkin, Maxim, additional, Olsson, Richard, additional, Perales, Miguel-Angel, additional, Rashidi, Armin, additional, Romee, Rizwan, additional, Saad, Ayman, additional, Seo, Sachiko, additional, Ulrickson, Matthew L., additional, Ustun, Celalettin, additional, Wirk, Baldeep M., additional, Woolfrey, Ann E., additional, Yared, Jean, additional, Pasquini, Marcelo C., additional, and Mineishi, Shin, additional

Published
2017
Full Text
View/download PDF

126. Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance Therapy for High Risk Multiple Myeloma

Author

Green, Damian J., primary, Maloney, David G., additional, Storer, Barry E., additional, Sandmaier, Brenda M., additional, Holmberg, Leona A., additional, Martin, Paul J., additional, Becker, Pamela S., additional, Georges, George E., additional, Bouvier, Michelle E., additional, Storb, Rainer, additional, and Mielcarek, Marco B., additional

Published
2017
Full Text
View/download PDF

127. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Alsina, Melissa, additional, Atanackovic, Djordje, additional, Biermann, J. Sybil, additional, Chandler, Jason C., additional, Costello, Caitlin, additional, Faiman, Matthew, additional, Fung, Henry C., additional, Gasparetto, Cristina, additional, Godby, Kelly, additional, Hofmeister, Craig, additional, Holmberg, Leona, additional, Holstein, Sarah, additional, Huff, Carol Ann, additional, Kassim, Adetola, additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Raje, Noopur, additional, Reu, Frederic J., additional, Singhal, Seema, additional, Somlo, George, additional, Stockerl-Goldstein, Keith, additional, Treon, Steven P., additional, Weber, Donna, additional, Yahalom, Joachim, additional, Shead, Dorothy A., additional, and Kumar, Rashmi, additional

Published
2017
Full Text
View/download PDF

129. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation

Author

Cheng, Yee Chung, primary, Shi, Yushu, additional, Zhang, Mei-Jie, additional, Brazauskas, Ruta, additional, Hemmer, Michael T., additional, Bishop, Michael R., additional, Nieto, Yago, additional, Stadtmauer, Edward, additional, Ayash, Lois, additional, Gale, Robert Peter, additional, Lazarus, Hillard, additional, Holmberg, Leona, additional, Lill, Michael, additional, Olsson, Richard F., additional, Wirk, Baldeep Mona, additional, Arora, Mukta, additional, Hari, Parameswaran, additional, and Ueno, Naoto, additional

Published
2017
Full Text
View/download PDF

130. Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission

Author

Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Fromm, Jonathan R., Wu, David, Holmberg, Leona A., Till, Brian G., Chauncey, Thomas R., Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian, Libby, Edward N., Bensinger, William I., Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.

Subjects
Adult, Male, Neoplasm, Residual, Transplantation Conditioning, Remission Induction, Hematopoietic Stem Cell Transplantation, Lymphoma, Mantle-Cell, Middle Aged, Survival Analysis, Transplantation, Autologous, Article, body regions, hemic and lymphatic diseases, Humans, Female, Aged
Abstract

Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 2.38 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR.

Published
2015

133. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation

Author

Cowan, Andrew J., primary, Klippel, Zandra K., additional, Stevenson, Philip A., additional, Hyun, Teresa S., additional, Tuazon, Sherilyn, additional, Becker, Pamela S., additional, Green, Damian J., additional, Holmberg, Leona A., additional, Coffey, David G., additional, Gopal, Ajay K., additional, and Libby, Edward N., additional

Published
2016
Full Text
View/download PDF

134. Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Author

Ebadi, Maryam, Fan, Xinyi, Schoch, Gary, Gooley, Ted, Rashidi, Armin, Smith, Stephen D, Shadman, Mazyar, Holmberg, Leona, Ujjani, Chaitra S, Poh, Christina, Raghunathan, Vikram, Ali, Naveed, Vo, Phuong T, Manjappa, Shivaprasad, Menon, Manoj, Lynch, Ryan C, Ho, Carrie I, Till, Brian G, Ermoian, Ralph, Gopal, Ajay K, and Tseng, Yolanda D

Abstract

Introduction

Published
2023
Full Text
View/download PDF

135. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

Author

Onishi, Maika, Graf, Solomon A., Holmberg, Leona, Behnia, Sanaz, Shustov, Andrei R., Schiavo, Karen, Philip, Mary, Libby, Edward N., Cassaday, Ryan D., Pagel, John M., Roden, Jennifer E., Maloney, David G., Green, Damian J., Till, Brian G., Press, Oliver W., Smith, Stephen D., and Gopal, Ajay K.

Subjects
Adult, Brentuximab Vedotin, Male, Immunoconjugates, Adolescent, Middle Aged, Prognosis, Hodgkin Disease, Article, Young Adult, Treatment Outcome, Fluorodeoxyglucose F18, Positron-Emission Tomography, Humans, Female, Platinum
Abstract

Normalization of fluorodeoxyglucose positron emission tomography (FDG PET) imaging prior to high-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes in relapsed and refractory (RR) Hodgkin lymphoma (HL), but many patients refractory to platinum-based salvage regimens are unable to achieve this goal. We therefore investigated whether brentuximab vedotin (BV) could normalize FDG PET in platinum-refractory HL prior to ASCT. Fifteen consecutive patients with RR HL and FDG PET positive disease after platinum-based salvage therapy were treated with a median of 4 cycles of BV. Normalization of FDG PET (Deauville ≤2) occurred in 8/15 (53%) patients but was only observed in patients that had achieved partial remission or stable disease after platinum-based salvage therapy. All patients eventually proceeded to ASCT, regardless of FDG PET status. Our data suggest that BV can normalize FDG PET in a subset of patients with platinum-refractory HL prior to ASCT.

Published
2014

136. Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation

Author

Cassaday, Ryan D., Guthrie, Katherine A., Budde, Elizabeth L., Thompson, Leslie, Till, Brian G., Press, Oliver W., Chauncey, Thomas R., Pagel, John M., Petersdorf, Stephen H., Palanca-Wessels, Maria Corinna, Philip, Mary, Bensinger, William I., Holmberg, Leona A., Shustov, Andrei, Green, Damian J., Libby, Edward N., Maloney, David G., and Gopal, Ajay K.

Published
2013
Full Text
View/download PDF

137. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

Author

Anderson, Kenneth C., primary, Alsina, Melissa, additional, Atanackovic, Djordje, additional, Biermann, J. Sybil, additional, Chandler, Jason C., additional, Costello, Caitlin, additional, Djulbegovic, Benjamin, additional, Fung, Henry C., additional, Gasparetto, Cristina, additional, Godby, Kelly, additional, Hofmeister, Craig, additional, Holmberg, Leona, additional, Holstein, Sarah, additional, Huff, Carol Ann, additional, Kassim, Adetola, additional, Krishnan, Amrita Y., additional, Kumar, Shaji K., additional, Liedtke, Michaela, additional, Lunning, Matthew, additional, Raje, Noopur, additional, Reu, Frederic J., additional, Singhal, Seema, additional, Somlo, George, additional, Stockerl-Goldstein, Keith, additional, Treon, Steven P., additional, Weber, Donna, additional, Yahalom, Joachim, additional, Shead, Dorothy A., additional, and Kumar, Rashmi, additional

Published
2016
Full Text
View/download PDF

138. Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma

Author

Gauthier, Jordan, primary, Holmberg, Leona, additional, Wu, David, additional, Bensinger, William I., additional, Gopal, Ajay K., additional, Press, Oliver W., additional, Maloney, David G, additional, Green, Damian J., additional, Till, Brian G., additional, Byelykh, Denys, additional, and Shustov, Andrei R., additional

Published
2015
Full Text
View/download PDF

139. Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Author

Chen, Robert, primary, Palmer, Joycelynne, additional, Holmberg, Leona, additional, Alluin, Jessica, additional, Chomchan, Pritsana, additional, Popplewell, Leslie L., additional, Siddiqi, Tanya, additional, Thomas, Sandra H., additional, Irenze, Kathryn, additional, Nademanee, Auayporn P., additional, Spielberger, Ricardo, additional, Rossi, John J, additional, Rosen, Steven T., additional, Kwak, Larry W., additional, and Forman, Stephen J., additional

Published
2015
Full Text
View/download PDF

140. Multiple Myeloma, Version 2.2016

Author

Anderson, Kenneth C., primary, Alsina, Melissa, additional, Atanackovic, Djordje, additional, Biermann, J. Sybil, additional, Chandler, Jason C., additional, Costello, Caitlin, additional, Djulbegovic, Benjamin, additional, Fung, Henry C., additional, Gasparetto, Cristina, additional, Godby, Kelly, additional, Hofmeister, Craig, additional, Holmberg, Leona, additional, Holstein, Sarah, additional, Huff, Carol Ann, additional, Kassim, Adetola, additional, Krishnan, Amrita Y., additional, Kumar, Shaji K., additional, Liedtke, Michaela, additional, Lunning, Matthew, additional, Raje, Noopur, additional, Singhal, Seema, additional, Smith, Clayton, additional, Somlo, George, additional, Stockerl-Goldstein, Keith, additional, Treon, Steven P., additional, Weber, Donna, additional, Yahalom, Joachim, additional, Shead, Dorothy A., additional, and Kumar, Rashmi, additional

Published
2015
Full Text
View/download PDF

141. 329 - Safety and Efficacy of Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

Author

Cassaday, Ryan D., Press, Oliver W., Pagel, John M., Rajendran, Joseph G., Gooley, Ted Alan, Fisher, Darrell R., Miyaoka, Robert S., Maloney, David G., Smith, Stephen D., Till, Brian G., Martin, Daniel B., Holmberg, Leona A., Green, Damian J., and Gopal, Ajay K.

Published
2018
Full Text
View/download PDF

145. Allogeneic Stem Cell Transplantation for Multiple Myeloma: A Review of Outcomes at a single Transplant Center

Author

Bensinger, William, Rotta, Marcello, Storer, Barry, Chauncey, Tom, Holmberg, Leona, Becker, Pam, Sandmaier, Brenda M., Storb, Rainer, and Maloney, David

Subjects
Adult, Male, Time Factors, Transplantation Conditioning, Middle Aged, Article, Disease-Free Survival, Survival Rate, surgical procedures, operative, Humans, Transplantation, Homologous, Female, Multiple Myeloma, Aged, Retrospective Studies, Stem Cell Transplantation
Abstract

Allogeneic stem cell transplant for multiple myeloma (MM) is one treatment associated with long term disease free survival. The high incidence of treatment related mortality and relapses, however, are important reasons for controversy about the role of allografting in the management of MM. We reviewed our results of allografting for MM spanning a period of 34 years in order to better define long term outcomes and identify areas of progress as well as areas needing improvement. A total of 278 patients received allogeneic marrow or peripheral blood stem cells after high dose myeloablative (N=144) or reduced intensity, non-myeloablative (N=134) regimens. In multivariable analysis, adjusting for differences in patient groups, reduced intensity/nonmyeloablative transplants were associated with significantly less acute GVHD, lower transplant mortality, better progression free survival and overall survival. There were no significant differences in relapse, progression or chronic GVHD, when adjusted. In multivariable analysis of patients receiving only non-myeloablative transplants, decreased overall survival and progression free survival were associated with relapse after a prior autograft and a β2 microglobulin >4.0. Transplant mortality was reduced and only influenced by a prior tandem autograft.

Published
2012

146. A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Author

Chow, Victor A., Rajendren, Joseph, Shields, Andrew, Fisher, Darrell R., Appelbaum, Frederick R., Cassaday, Ryan D., Cowan, Andrew J., Martin, Paul J., Holmberg, Leona, Gooley, Ted, Stevenson, Philip A., Pagel, John M., Green, Damian J., Press, Oliver W., and Gopal, Ajay K.

Published
2017
Full Text
View/download PDF

147. New Cancers after Autotransplantations for Multiple Myeloma

Author

Mahindra, Anuj, primary, Raval, Girindra, additional, Mehta, Paulette, additional, Brazauskas, Ruta, additional, Zhang, Mei-Jie, additional, Zhong, Xiaobo, additional, Bird, Jennifer M., additional, Freytes, César O., additional, Hale, Gregory A., additional, Herzig, Roger, additional, Holmberg, Leona A., additional, Kamble, Rammurti T., additional, Kumar, Shaji, additional, Lazarus, Hillard M., additional, Majhail, Navneet S., additional, Marks, David I., additional, Moreb, Jan S., additional, Olsson, Richard, additional, Saber, Wael, additional, Savani, Bipin N., additional, Schiller, Gary J., additional, Tay, Jason, additional, Vogl, Dan T., additional, Waller, Edmund K., additional, Wiernik, Peter H., additional, Wirk, Baldeep, additional, Lonial, Sagar, additional, Krishnan, Amrita Y., additional, Dispenzieri, Angela, additional, Brandenburg, Nancy A., additional, Gale, Robert Peter, additional, and Hari, Parameswaran N., additional

Published
2015
Full Text
View/download PDF

148. Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Author

Cowan, Andrew J., primary, Stevenson, Philip A., additional, Cassaday, Ryan D., additional, Graf, Solomon A., additional, Holmberg, Leona, additional, Fromm, Jonathan R., additional, Till, Brian G., additional, Wu, David, additional, Chauncey, Thomas, additional, Smith, Stephen D., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Shustov, Andrei R., additional, Green, Damian J., additional, Libby, Edward N., additional, Bensinger, William, additional, Shadman, Mazyar, additional, Maloney, David G., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2015
Full Text
View/download PDF

149. Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma

Author

Cassaday, Ryan D., primary, Stevenson, Philip A., additional, Gooley, Theodore A., additional, Chauncey, Thomas, additional, Pagel, John, additional, Till, Brian G., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Bensinger, William I., additional, Holmberg, Leona, additional, Shustov, Andrei R., additional, Green, Damian J., additional, Smith, Stephen D., additional, Libby, Edward N., additional, Maloney, David G, additional, Soma, Lorinda A., additional, Press, Oliver W., additional, and Gopal, Ajay K., additional

Published
2014
Full Text
View/download PDF

150. Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC+ B-Cell Lymphoma

Author

Cassaday, Ryan D., primary, Stevenson, Philip A., additional, Bryant, Bronwyn H., additional, Yeung, Cecilia, additional, Till, Brian G., additional, Smith, Stephen D., additional, Libby, Edward N., additional, Shustov, Andrei R., additional, Pagel, John M., additional, Green, Damian J., additional, Philip, Mary, additional, Orozco, Johnnie J., additional, Fang, Min, additional, Holmberg, Leona, additional, Bensinger, William I., additional, Maloney, David G, additional, Gopal, Ajay K., additional, and Press, Oliver W., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results